



Press release

VISTACARE MEDICAL AND QUANTUM GENOMICS ENTER INTO EXCLUSIVE NEGOTIATIONS WITH THE AMBITION OF CREATING A REFERENCE PLAYER IN THE MANAGEMENT OF COMPLEX WOUNDS

- *With the support of the medical community, VistaCare Medical is developing a revolutionary technology for treating complex wounds. Its medical device is already implemented in around thirty hospitals.*
- *Complex wounds represent a fast-growing market with unmet needs.*
- *The merger is scheduled to close in the 4th quarter of 2023.*

Besançon, July 20, 2023. VistaCare Medical, a French medtech company developing innovative technology for the treatment of complex wounds, and Quantum Genomics, a biopharmaceutical company listed on the Euronext Growth market in Paris (FR0011648971 - ALQGC), have entered into exclusive negotiations to create a **leading player in the field of complex wound management**.

VistaCare Medical has developed and marketed a patented medical device based on the **WEC™ therapy** (*Wound Environment Controlled*), which enables healthcare professionals to act directly on three essential parameters to accelerate the healing of complex wounds: oxygen content, temperature and hygrometry.

The WEC Therapy approach:

- reduces treatment time (hospital and home) to ensure complete healing for patients,
- halves the time needed to obtain optimal tissue for a covering procedure (from 20 to 10 days) compared with existing solutions;
- saves precious time for carers thanks to direct visualization of the wound, without having to change dressings or dedicated devices, and the generator's simple, intuitive operation, even for non-specialist healthcare professionals;
- improves the patient's quality of life and saves nursing staff time, thereby helping to reduce wound management costs.

Thanks to its breakthrough technology, VistaCare Medical has raised €7.2 million since its creation, including €4 million in capital from two investment funds, Cap Innov'Est (France) and Noshag (Belgium).

Quantum Genomics, a biopharmaceutical company developing new therapies for unmet medical needs, recently announced its intention to redeploy its business around a project with high technological value.

The merger of Quantum Genomics and VistaCare Medical will allow:

- the continued deployment of the patented VistaCare device, already implemented in

about thirty hospitals **in France** and potentially **in international markets with strong prospects** (Europe, United Arab Emirates, USA);

- further development towards **a connected ambulatory version**, providing effective treatment to all patients with complex wounds worldwide, **regardless of their treatment location, be it in hospitals or at home;**
- the continuation of R&D operations in Liège, supported by the Walloon Region, by its subsidiary VistaCare Medical Benelux.

The technological innovation offered by Vistacare Medical, the financial contribution, and the stock listing of Quantum Genomics, along with the complementary expertise of the teams, are all assets that should enable the new entity to establish a prominent position in the market for complex wound management, where unmet needs persist.

Approximately 1% of the European population and 2.5% of the US population suffer from chronic wounds. In France, about 1 million people suffer from complex wounds. The global wound care market is a voluminous and rapidly expanding market, projected to reach 18.7 billion dollars by 2027, with a compound annual growth rate (CAGR) of 6.6%. The market's growth is mainly attributed to the aging population and the increasing incidence of chronic diseases such as diabetes.

Supported by Otium Capital, main shareholder of Quantum Genomics, Noshag and Cap Innov'Est, the main shareholders of VistaCare Medical, the proposed capital merger would ultimately result in Quantum Genomics absorbing VistaCare Medical and would be carried out through a share exchange. The transaction is expected to close in the fourth quarter of 2023.

Upon completion of the proposed operation, Mr. Jean-Philippe Milon, CEO of Quantum Genomics, will resign from his position as CEO and become Chairman of the Board of Directors of the new entity. Mr. François Dufay, President and founder of Vistacare Medical, will become Chief Scientific Officer and a member of the Board of Directors of the new entity. Mr. Thierry Sarda, the current CEO of Vistacare Medical, will become CEO and a member of the Board of Directors of the new entity. Mr. Benoit Gueugnon, the current Chief Administrative and Financial Officer of Quantum Genomics, will retain his position. The Board of Directors of the new entity will be composed of members of the management, investors, and independent directors.

François Dufay, President and Founder of Vistacare Medical: *“The approach of WEC therapy developed by VistaCare Medical is radically different from conventional practices in the treatment of complex wounds. It gives patients a chance to heal through effective and reproducible treatment - regardless of their treatment location, including home care in the future, with the development of an ambulatory device. WEC therapy, currently used as a second-line treatment, is gradually becoming a first-line treatment alongside existing techniques in the services that use it routinely. The prospect of accelerating the development of Vistacare Medical through the merger with Quantum Genomics is excellent news to provide this therapeutic innovation to patients in need, in the best possible time and conditions.”*

Thierry Sarda, CEO of Vistacare Medical : *“I am delighted with this merger that will propel VistaCare Medical into a new dimension. The new financial and human resources provided by Quantum Genomics will enable us to accelerate our development in France and explore new international markets, with the aim of becoming a major player in the management of complex wounds.”*

Francois Durvye, CEO of Otium Capital, Quantum Genomics' leading shareholder and a historical leader in private equity in France, managing 1.2 billion euros in assets: *“We renew*

our full confidence in the Quantum Genomics team with whom we wish to continue this entrepreneurial adventure. This new project makes even more sense as it brings real technological innovation in an important area of healthcare with unmet needs and allows for the combination of complementary experiences, talents, and skills. We are pleased with the speed of Quantum Genomics' repositioning."

Jean-Philippe Milon, President and CEO of Quantum Genomics : *"This merger with Vistacare Medical comes after an in-depth strategic analysis conducted by our team to effectively reposition the company. As we had said, we sought collaboration with a company in the healthcare sector that meets four criteria: a major business area, an innovative and distinctive project, a know-how replicable internationally, and a high-performing team complementary to ours to support the project. These criteria naturally led us to take an interest in Vistacare Medical and its technological innovation, which meet all our selection criteria."*

Jean-François Rax, Member of the Management Board and Director of Participations at Cap Innov'Est: *"We are very happy to see VistaCare, whom we have been supporting since late 2014, enter a new phase of development. This operation will allow the company to fully deploy its commercial potential while continuing to develop its second product dedicated to home hospitalization. The human synergy between the teams of Quantum Genomics and VistaCare will make this merger a true success."*

Eric Brandt, Investment Manager at Noshaq: *"We fully support this merger initiative, as it will offer VistaCare Medical the opportunity to accelerate its commercial growth and expand internationally. The additional financial resources will also strengthen research and development activities, consolidating its position as a leader in the development of innovative solutions for contactless treatment of complex wounds. We congratulate the management of both companies for this merger."*

About VistaCare Medical:

VistaCare Medical, a pioneer in the treatment of complex wounds, was founded by François Dufaÿ, a physiotherapist and osteopath by training. Its revolutionary wound treatment is based on WEC (*wound environment controlled*) technology, which requires no dressing and no contact. After raising €4 million in January 2022 and deploying in around thirty hospitals, VistaCare Medical is continuing its commercial and R&D roll-out, opening up promising prospects by developing the ambulatory version of its device through its Liège-based subsidiary, VistaCare Medical Benelux. Its ambition is to become the new standard of care for the treatment of complex wounds.

Press contacts :

Bien Commun Advisory

Bénédicte Debusschère - b.debusschere@bcadvisory.fr - +33 (0)6 48 56 70 71

Thierry Koumagnon - t.koumagnon@bcadvisory.fr - +33 (0)7 82 38 58 35